7 citations,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
52 citations,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
4 citations,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
December 2021 in “Research Square (Research Square)” Hair growth-promoting nutraceuticals do not block the cancer-fighting effects of tamoxifen and may enhance its action.
February 2022 in “Research Square (Research Square)” Certain nutraceuticals may enhance hair growth without affecting the cancer-fighting properties of tamoxifen.
7 citations,
May 2016 in “SpringerPlus” Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.
1 citations,
June 2022 in “Journal of Clinical Oncology” Oral minoxidil may help hair regrowth in female cancer survivors.
December 2022 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil combined with topical minoxidil improves hair growth in breast cancer patients with therapy-induced hair loss.
4 citations,
November 2021 in “Cancers” The document concludes that understanding and managing hair loss in cancer patients is important, and more research is needed for better treatments.
67 citations,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
March 2023 in “Journal of Cosmetic Dermatology” Low-dose oral minoxidil improved hair growth when topical treatments failed.
1 citations,
April 2022 in “Indian Journal of Plastic Surgery” Hormone therapy greatly improves the quality of life for adults seeking gender reaffirmation, but more research is needed in India.
1 citations,
June 2018 in “JAMA Dermatology” Vitamin C was found to effectively treat prickly heat in children.
855 citations,
June 2009 in “The Journal of Clinical Endocrinology & Metabolism” The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.
September 2024 in “Journal of the American Academy of Dermatology” PRP treatment may help improve hair density and thickness in breast cancer patients with therapy-induced hair loss.
4 citations,
May 2019 in “Journal of Clinical Oncology” Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
45 citations,
March 2015 in “Clinical Endocrinology” Testosterone therapy is generally safe for transmen, improves sexual function, and has manageable health risks with proper monitoring.
9 citations,
April 2018 in “JAMA Dermatology” Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
Certain drugs can worsen hair loss in people prone to androgenetic alopecia.
10 citations,
May 2009 in “Sexual and Relationship Therapy” The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.
August 2021 in “Pediomaternal Nursing Journal” Endocrine therapy helps with reproductive and metabolic issues in women with PCOS.
43 citations,
March 2019 in “JAMA Dermatology” Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
10 citations,
May 2018 in “Neuropharmacology” Drugs for hormone-related conditions might help treat mental disorders but could have serious side effects.
3 citations,
July 2018 in “Cureus” A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.
March 2023 in “JAAD case reports”
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
January 2012 in “S. Karger AG eBooks” The document concludes that transsexual individuals often experience improved quality of life after transitioning, despite higher risks of psychiatric issues and mortality.
11 citations,
January 1991 in “Urology” New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.